Survival outcomes and the role of DNADX ctDNA testing in patients treated with sacituzumab govitecan for metastatic breast cancer
Rattachement africain : us, es, fr. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: Sacituzumab govitecan (SG) is an anti-trop2 antibody-drug conjugate (ADC) approved for human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC). However, data on effectiveness of SG and biomarkers remain limited. DNADX is a plasma-only multi-gene signature assay that identifies five tumor subtypes. In previous studies, DNADX subtypes have been associated with clinical outcomes. MATERIALS AND METHODS: This study included patients with MBC treated with SG monotherapy between June 2014 and January 2023. Clinicopathological features and outcomes [time to next treatment (TTNT), overall survival (OS)] were analyzed. An exploratory analysis evaluated the association between DNADX subtypes and outcomes. RESULTS: A total of 121 patients with triple-negative breast cancer (TNBC), 59 with hormone receptor (HR)-positive/HER2-negative MBC, and 4 with HER2-positive MBC at the time of SG initiation were identified. Visceral disease was present in 75% of patients; 23.4% had brain metastases. Patients with TNBC had a median of 3 (range 0-9) prior lines for MBC, including chemotherapy (91%), immunotherapy (53%), and trastuzumab deruxtecan (T-DXd) (3%). Those with HR-positive/HER2-negative MBC had received a median of 5 (range 0-14) prior lines, including chemotherapy (97%), cyclin-dependent kinase 4/6 inhibitors (78%), immunotherapy (25%), and T-DXd (12%). Median TTNT was 4.3 months [95% confidence interval (CI) 3.7-5.0 months] for TNBC and 4.2 months (95% CI 2.8-4.9 months) for HR-positive/HER2-negative MBC. Median OS was 10.4 months (95% CI 8.0-13.3 months) for TNBC and 10.2 months (95% CI 7.0-12.6 months) for HR-positive/HER2-negative MBC. DNADX subtypes were significantly associated with outcomes. The tumor fraction (TF)-low subtype was linked to the longest TTNT and OS, while the proliferative and basal-related subtypes were associated with poorer outcomes. CONCLUSIONS: Outcomes observed with SG were consistent with those reported in the registrational trials. DNADX subtypes were associated with TTNT and OS, underscoring their potential as biomarkers. Improved therapeutic options in the post-ADC setting and better biomarkers for treatment sequencing are urgently needed.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Survival outcomes and the role of DNADX ctDNA testing in patients treated with sacituzumab govitecan for metastatic breast cancer
- Date Crossref
- 01/10/2025
- Éditeur
- Elsevier BV
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Broad Institute pays non établi dans la noticeOrganisation à but non lucratif
-
Dana-Farber Cancer Institute pays non établi dans la noticeStructure de recherche
-
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer pays non établi dans la noticeStructure de recherche
-
Vall d'Hebron Institut de Recerca pays non établi dans la noticeStructure de recherche
-
Vall d'Hebron Hospital Universitari pays non établi dans la noticeÉtablissement de santé
-
Institut Gustave Roussy pays non établi dans la noticeStructure de recherche
-
Oryzon Genomics (Spain) pays non établi dans la noticeEntreprise
-
Hospital Clínic de Barcelona pays non établi dans la noticeÉtablissement de santé
-
Dana-Farber/Harvard Cancer Center pays non établi dans la noticeÉtablissement de santé
-
August Pi i Sunyer Biomedical Research Institute (IDIBAPS) Spain pays non établi dans la noticeStructure de recherche
-
VHIO Vall d'Hebron Institute of Oncology USA pays non établi dans la noticeStructure de recherche
-
Reveal Genomics pays non établi dans la noticeInstitution
Broad Institute, Dana-Farber Cancer Institute et Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.